TODD AUGUSTUS: Open Payments
NPI 1912168238 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,524 in 14 payments from 7 companies in 2025. Trend: 2023 $248 · 2024 $1,299 · 2025 $1,524
Food & beverage: $1,524
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 3 | $306 |
| Vanda Pharmaceuticals Inc. | 3 | $262 |
| E.R. Squibb & Sons, L.L.C. | 2 | $247 |
| Otsuka America Pharmaceutical, Inc. | 2 | $241 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $230 |
| Alkermes, Inc. | 1 | $120 |
| Axsome Therapeutics, Inc. | 1 | $119 |
Products named: INGREZZA, FANAPT, COBENFY, CAPLYTA, REXULTI, ARISTADA, ABILIFY MAINTENA, Auvelity.
Industry payments across DC — which companies pay providers there.
